How Successful is Switching from Bevacizumab or Ranibizumab to Aflibercept in Age-Related Macular Degeneration? A Systematic Overview
Open Access
- 17 May 2019
- journal article
- review article
- Published by Springer Nature in Advances in Therapy
- Vol. 36 (7) , 1532-1548
Abstract
Emerging anti-vascular endothelial growth factor (anti-VEGF) therapies for neovascular age-related macular degeneration (nAMD) have revolutionised medical retina practice and the management and eventual outcome of nAMD. Recent research has focused on evaluating and comparing the efficacy of the two most widely employed anti-VEGF agents, bevacizumab and ranibizumab; however, a subgroup of patients with nAMD demonstrates a suboptimal response to standard therapy. We have therefore conducted a review of pertinent studies published until August 2018 which have documented the clinical efficacy when switching to a different anti-VEGF. Evidence on baseline disease characteristics, injection frequency and disease outcome has been obtained for patients treated with ranibizumab 0.5 mg and/or bevacizumab 1.25 mg and were switched to aflibercept 2 mg. Our review identified 45 studies investigating switching to aflibercept. Our review showed a clear anatomical benefit after the switch in terms of central retinal thickness and pigment epithelium detachment characteristics, whereas the functional outcomes were variable. Remarkable heterogeneity was documented among the relevant studies with regard to several factors including the baseline characteristics of the cohorts, the non-response definition and previous treatment protocols. Larger prospective trials with appropriate control arms are therefore required to elucidate the potential benefit when switching between anti-VEGF agents in refractory nAMD.Keywords
This publication has 67 references indexed in Scilit:
- Exploring the Use of Molecular Biomarkers for Precision Medicine in Age-Related Macular DegenerationMolecular Diagnosis & Therapy, 2018
- Vision-related quality of life: 12-month aflibercept treatment in patients with treatment-resistant neovascular age-related macular degenerationGraefe's Archive for Clinical and Experimental Ophthalmology, 2016
- Intravitreal aflibercept in treatment-resistant pigment epithelial detachmentInternational Ophthalmology, 2016
- The short-term effects of aflibercept on the size of choroidal neovascularization lesion in treatment-resistant neovascular age-related macular degeneration as determined by spectral-domain optical coherence tomographyLasers in Surgery and Medicine, 2016
- Intravitreal aflibercept for ranibizumab-resistant exudative age-related macular degeneration with choroidal vascular hyperpermeabilityJapanese Journal of Ophthalmology, 2015
- Effects of aflibercept for ranibizumab-resistant neovascular age-related macular degeneration and polypoidal choroidal vasculopathyGraefe's Archive for Clinical and Experimental Ophthalmology, 2014
- The Economic Burden of Major Adult Visual Disorders in the United StatesArchives of Ophthalmology (1950), 2006
- Age-Related Macular Degeneration Is the Leading Cause of Blindness . . .JAMA, 2004
- Utility Values and Age-related Macular DegenerationArchives of Ophthalmology (1950), 2000
- MECHANICS OF OPTIC NERVE TRACTION ON THE RETINA DURING OCULAR ROTATIONArchives of Ophthalmology (1950), 1941